Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1046532 | 0.88 | ALOX5 (0.41) | TRPA1ALOX5PYCR1CYP1A2HTR2A | |
| SCHEMBL19262290 | 0.88 | ALOX5 (0.41) | TRPA1ALOX5PYCR1CYP1A2HTR2A | |
| SCHEMBL1653943 | 0.82 | TRPA1 (0.48) | TRPA1ESR1ESR2SMN1; SMN2RIPK1 | |
| SCHEMBL3858792 | 0.82 | ABCB11 (0.44) | TRPA1ALOX5PYCR1CYP1A2HTR2A | |
| SCHEMBL5878306 | 0.82 | ABCB11 (0.44) | TRPA1ALOX5PYCR1CYP1A2HTR2A | |
| SCHEMBL3858793 | 0.82 | ABCB11 (0.44) | TRPA1ALOX5PYCR1CYP1A2HTR2A | |
| SCHEMBL11545120 | 0.81 | TRPA1 (0.39) | TRPA1ALOX5PYCR1 | |
| SCHEMBL17946512 | 0.80 | ALOX5 (0.39) | TRPA1ALOX5PYCR1CYP1A2RIPK1 | |
| SCHEMBL24493292 | 0.80 | PYCR1 (0.43) | ALOX5PYCR1CYP1A2MAOAHTR2A | |
| SCHEMBL10273168 | 0.80 | PYCR1 (0.43) | ALOX5PYCR1CYP1A2HTR2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567443-B | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-28 | — | — | CN | disclosed |
| CN-115925679-A | Biaryl derivatives as GPR120 agonists | 株式会社LG化学 | 2023-04-07 | — | — | CN | disclosed |
| EP-3239143-B1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEMICAL LTD (KR) | 2023-03-22 | — | — | EP | disclosed |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | LG CHEM. LTD. (KR) | 2022-03-01 | — | — | US | disclosed |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG CHEM, LTD. (KR) | 2017-12-07 | — | — | US | disclosed |
| EP-3239143-A2 | BIARYL DERIVATIVE AS GPR120 AGONIST | LG Chem, Ltd. (KR) | 2017-11-01 | — | — | EP | disclosed |
| US-9409865-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation_Pharmaceuticals, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409865-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation_Pharmaceuticals, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409865-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | Constellation_Pharmaceuticals, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| WO-2013075084-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013075084-A1 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2013-05-23 | — | — | WO | disclosed |
| US-8318767-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | SCHERING CORPORATION | 2012-04-12 | — | — | US | disclosed |
| US-8106070-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | ALBANY MOLECULAR RESEARCH, INC. | 2010-01-07 | — | — | US | disclosed |
| EP-2083822-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051404-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| CN-1097051-C | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 2002-12-25 | — | — | CN | disclosed |
| CN-1192739-A | N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists | ZENECA LTD (GB) | 1998-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | BRS3, GPR119, GIPR | TRPA1 245/4885ALOX5 4703/4885PYCR1 2566/4885 |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | TRPA1 245/4885ALOX5 4703/4885PYCR1 2566/4885 |
| US-20220135574-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | TRPA1 1198/4885ALOX5 851/4885PYCR1 1275/4885 |
| US-20170349594-A1 | BIARYL DERIVATIVE AS GPR120 AGONIST | GPR119, GLP1R, GIPR | TRPA1 1198/4885ALOX5 851/4885PYCR1 1275/4885 |
| US-11261186-B2 | Biaryl derivative as GPR120 agonist | GPR119, GPR88, FFAR1 | TRPA1 720/4885ALOX5 486/4885PYCR1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.